PALI Stock Overview
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Palisade Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.60 |
| 52 Week High | US$36.60 |
| 52 Week Low | US$3.82 |
| Beta | 1.46 |
| 1 Month Change | 21.31% |
| 3 Month Change | -16.98% |
| 1 Year Change | -76.47% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.91% |
Recent News & Updates
Recent updates
Palisade Bio announces CEO transition
Oct 11Palisade Bio streamlines operations, including cutting 20% of employees
Sep 15Palisade Bio GAAP EPS of -$0.12
Aug 15Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function
Jul 27Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy
Jun 29Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely
Mar 28
Palisade Bio: Guarding Intestinal Integrity
Nov 07Shareholder Returns
| PALI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 62.2% | -2.2% | -3.7% |
| 1Y | -76.5% | 11.6% | 20.5% |
Return vs Industry: PALI underperformed the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: PALI underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| PALI volatility | |
|---|---|
| PALI Average Weekly Movement | 30.9% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PALI's share price has been volatile over the past 3 months.
Volatility Over Time: PALI's weekly volatility has increased from 26% to 31% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 9 | J. Finley | www.palisadebio.com |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company’s lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd.
Palisade Bio, Inc. Fundamentals Summary
| PALI fundamental statistics | |
|---|---|
| Market cap | US$5.05m |
| Earnings (TTM) | -US$12.32m |
| Revenue (TTM) | US$250.00k |
22.5x
P/S Ratio-0.5x
P/E RatioIs PALI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PALI income statement (TTM) | |
|---|---|
| Revenue | US$250.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$250.00k |
| Other Expenses | US$12.57m |
| Earnings | -US$12.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.47 |
| Gross Margin | 100.00% |
| Net Profit Margin | -4,926.40% |
| Debt/Equity Ratio | 1.4% |
How did PALI perform over the long term?
See historical performance and comparison